| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/11/2002 | US6403554 Amides of retinoic acids, arachidonic, docosahexaenoic, eicosapentaenoic, or linoleic acids with 2-aminoethanol, alpha-l-serine, alpha-l-threonine, alpha-l-tyrosine containing phosphate groups; complex with alpha fetoprotein, cancer |
| 06/11/2002 | US6403370 Generation an infection, reproduction, genetic engineering |
| 06/11/2002 | US6403349 Elongation of polyunsaturated fatty acid such as linolenic acid to dihomogamma linolenic acid; nucleotide sequence encodes polypeptide; genetic engineering; animal feeds, nutrients, cosmetics |
| 06/11/2002 | US6403345 Culturing, fermentation, obtaining biomass; purification; foods, drugs, cosmetics |
| 06/11/2002 | US6403335 Amino acid sequence; promotes survival of mesencephalic cells; nervous system and degenerative disorders; parkinson*s disease; genetic engineering |
| 06/11/2002 | US6403318 Fatty acid synthase mRNA binding protein |
| 06/11/2002 | US6403095 Treatment of primary and metastatic neoplastic diseases with HSP70-peptide complexes |
| 06/11/2002 | US6403091 Produced by the hybridoma having atcc accession no. hb 10916. |
| 06/11/2002 | US6403089 Inhibitors of fgl2; bacterial and viral infections, allograft and xenograft rejection, glomerulonephritis, cancer, gastrointestinal diseases and fetal loss; monoclonal and polyclonal antibodies which bind to fgl2 and prevent fibrin |
| 06/11/2002 | US6403083 Antitumor, anticancer agents; mixture containing mycelium and carrier |
| 06/11/2002 | US6403080 Methods of modulating an immune response to antigen, and cells for use in the method |
| 06/11/2002 | US6403079 Using polypeptide |
| 06/11/2002 | US6403077 Treatment regimes featuring an IL-10-containing chimeric polypeptide |
| 06/11/2002 | US6403054 Ternary ligand complexes useful as radiopharmaceuticals |
| 06/11/2002 | US6402037 Two-photon upconverting dyes and applications |
| 06/11/2002 | CA2198578C Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
| 06/11/2002 | CA2124218C Cytotoxic drug therapy |
| 06/11/2002 | CA2057441C Synthetic conversion of bryostatin 2 into bryostatin 1 |
| 06/09/2002 | WO2002067993A1 Drug-releasing system of biodegradable polymer type |
| 06/06/2002 | WO2002044734A1 Method for diagnosing a tumor in a patient determining the concentration of pibf |
| 06/06/2002 | WO2002044419A2 Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 06/06/2002 | WO2002044418A2 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 06/06/2002 | WO2002044417A2 Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer |
| 06/06/2002 | WO2002044396A1 Photochemical internalization for delivery of molecules into the cytosol |
| 06/06/2002 | WO2002044395A1 Photochemical internalization for virus-mediated molecule delivery into the cyosol |
| 06/06/2002 | WO2002044384A2 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy |
| 06/06/2002 | WO2002044383A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| 06/06/2002 | WO2002044379A2 Transforming growth factor-beta-related molecules and uses thereof |
| 06/06/2002 | WO2002044371A1 Human protooncogene and protein encoded therein |
| 06/06/2002 | WO2002044370A1 Human cervical cancer 2 protooncogene and protein encoded therein |
| 06/06/2002 | WO2002044368A1 Novel g protein-coupled receptor proteins and dnas thereof |
| 06/06/2002 | WO2002044364A2 Polypeptides involved in immune response |
| 06/06/2002 | WO2002044360A2 Modified arginine deiminase |
| 06/06/2002 | WO2002044347A1 A virus which can express tumor angiostatin factor with high efficiency in specific tumor cells and the use of it |
| 06/06/2002 | WO2002044342A2 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof |
| 06/06/2002 | WO2002044321A2 Rna interference mediating small rna molecules |
| 06/06/2002 | WO2002044320A2 Human elongase genes and uses thereof |
| 06/06/2002 | WO2002044209A2 Cytonkine receptor zcytor19 |
| 06/06/2002 | WO2002044202A2 Mutated immunogenic peptides derived from r9m, polynucleotides coding for same and therapeutic uses thereof |
| 06/06/2002 | WO2002044183A2 Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors |
| 06/06/2002 | WO2002044174A2 3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors |
| 06/06/2002 | WO2002044168A2 Indole-type inhibitors of p38 kinase |
| 06/06/2002 | WO2002044167A1 Process for the crystallization of (r)- or (s)-lansoprazole |
| 06/06/2002 | WO2002044166A1 Substituted quinolines as antitumor agents |
| 06/06/2002 | WO2002044164A1 0ovel farnesyl protein transferase inhibitors |
| 06/06/2002 | WO2002044162A1 Chromatographic separation method of paclitaxel and cephalomannin |
| 06/06/2002 | WO2002044161A2 A process for the preparation of taxan derivatives |
| 06/06/2002 | WO2002044158A1 Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents |
| 06/06/2002 | WO2002044157A2 Parb inhibitors |
| 06/06/2002 | WO2002044156A2 Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
| 06/06/2002 | WO2002044153A1 4-6-diphenyl pyridine derivatives as antiinflammatory agents |
| 06/06/2002 | WO2002044149A1 Indole and dihydroindole derivatives |
| 06/06/2002 | WO2002044147A1 Process for preparing distamycin derivatives |
| 06/06/2002 | WO2002044120A1 Compounds active at the glucocorticoid receptor iii |
| 06/06/2002 | WO2002043776A2 Neuropeptide y1 receptor binding compounds in the treatment and diagnosis of cancer |
| 06/06/2002 | WO2002043772A2 Water-soluble polymer conjugates of triazine derivatives |
| 06/06/2002 | WO2002043771A2 Conjugates of glycosylated/galactosylated peptide |
| 06/06/2002 | WO2002043766A1 Medicinal compositions and process for producing the same |
| 06/06/2002 | WO2002043765A2 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| 06/06/2002 | WO2002043757A2 Medicament for preventing or treating tumors caused by human papilloma virus type 18 |
| 06/06/2002 | WO2002043756A2 Method for obtaining antigenic aggregates and the use thereof in formulations |
| 06/06/2002 | WO2002043752A1 Interferon therapeutic effect-potentiating agents |
| 06/06/2002 | WO2002043741A2 Methylenetetrahydrofolate reductase inhibitors and use thereof |
| 06/06/2002 | WO2002043730A1 Use of mdr-1 inducers for treating or preventing diseases |
| 06/06/2002 | WO2002043728A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 06/06/2002 | WO2002043721A1 Treatment of statin side effects |
| 06/06/2002 | WO2002043718A2 Chemotherapeutic agents for the treatment of angiogenic diseases |
| 06/06/2002 | WO2002043716A2 Method for regulating prostate gland volume with insulin sensitizers |
| 06/06/2002 | WO2002043699A2 Preparation of large liposomes by infusion into peg |
| 06/06/2002 | WO2002043664A2 Reducing cellular damage in the human body |
| 06/06/2002 | WO2002043663A2 Tetrapartate prodrugs |
| 06/06/2002 | WO2002043661A2 Recombinant anti-cd30 antibodies and uses thereof |
| 06/06/2002 | WO2002043652A2 Anti-proliferative drugs |
| 06/06/2002 | WO2002043651A2 Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| 06/06/2002 | WO2002043648A2 Compounds active at the glucocorticoid receptor ii |
| 06/06/2002 | WO2002043647A2 Oncolytic virus |
| 06/06/2002 | WO2002043618A1 Methods for contemporaneous administration of levamisole and 5-fluorouracil |
| 06/06/2002 | WO2002043586A1 Method and device for measuring body compositions |
| 06/06/2002 | WO2002043570A2 METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES |
| 06/06/2002 | WO2002043567A2 A method of treating cancer |
| 06/06/2002 | WO2002028895A3 Cyclic peptides, method for preparing same and use as angiogenesis inhibitor or activator |
| 06/06/2002 | WO2002024665A8 Arylalkane-sulfonamides having endothelin-antagonist activity |
| 06/06/2002 | WO2002022616A3 Alpha v integrin receptor antagonists |
| 06/06/2002 | WO2002020483A8 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 06/06/2002 | WO2002013804A3 Method of treating angiogenesis-related disorders using benzoyl phenylacetic acid |
| 06/06/2002 | WO2002012242A3 Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| 06/06/2002 | WO2002010764A3 SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY |
| 06/06/2002 | WO2002005843A3 Human rrp sequences and methods of use |
| 06/06/2002 | WO2002000906A3 Replication deficient adenoviral tnf vector |
| 06/06/2002 | WO2001098359A3 Cyr61 as a target for treatment and diagnosis of breast cancer |
| 06/06/2002 | WO2001096542A3 A human aminotransferase (23680) and uses thereof |
| 06/06/2002 | WO2001094293A3 Benzamide ligands for the thyroid receptor |
| 06/06/2002 | WO2001093841A3 Barbituric acid analogs as therapeutic agents |
| 06/06/2002 | WO2001090334A3 Drug metabolizing enzymes |
| 06/06/2002 | WO2001090068A3 Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use a modulators of protein kinases |
| 06/06/2002 | WO2001089576A3 Preparation hypericin bonded with poly-n-vinylamides |
| 06/06/2002 | WO2001088116A9 Method of modulating activation of lymphocytes via modulation of pituitary tumor transforming gene, related screeining methods |
| 06/06/2002 | WO2001087849A3 Modulators of tnf- alpha signaling |
| 06/06/2002 | WO2001087238A3 Induction of apoptosis and cell growth inhibition by protein 4.33 |
| 06/06/2002 | WO2001080840A3 Cytotoxic agents comprising single-stranded and/or looped dna |